Cargando…

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients

BACKGROUND: Secondary oral vancomycin prophylaxis (OVP) has been utilized in adults with a history of Clostridioides difficile infection (CDI) while receiving systemic antibiotics to prevent CDI recurrence. However, this practice is poorly described in pediatric patients. Rates of CDI recurrence in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Hongkai, Dubrovskaya, Yanina, Papadopoulos, John, Siegfried, Justin, Merchan, Cristian, Lighter, Jennifer, Jen, Shin-Pung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776349/ http://dx.doi.org/10.1093/ofid/ofaa439.1558

Ejemplares similares

2412. Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side-effects: Two Hospitals Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

1441. Comparison of Cefpodoxime vs. Oral Cefuroxime for Urinary Tract Infections at a Large Academic Medical Center
por: Bao, Hongkai, et al.
Publicado: (2019)

Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia
por: Wo, Stephanie, et al.
Publicado: (2020)

270. Clinical Outcomes of Ceftriaxone versus Penicillin G for Complicated Viridans Group Streptococci Bacteremia
por: Wo, Stephanie, et al.
Publicado: (2020)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

2413. Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections.
por: Vyas, Nikunj M, et al.
Publicado: (2019)

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

Eight Years of Antimicrobial Stewardship Program (ASP) at a Large Academic Medical Center: Antibiotic Utilization, Hospital-onset Clostridium difficile infection (HO-CDI) and Resistance Trends
por: Dubrovskaya, Yanina, et al.
Publicado: (2017)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

Short vs. (vs) Prolonged Course of Therapy for Ventilator-associated Tracheitis (VAT) Caused by Non-lactose-fermenting Gram-negative Rods (NLFGNR) in the Pediatric Intensive Care Unit (PICU)
por: Fong, Karen, et al.
Publicado: (2017)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Analysis of the impact of secondary prophylaxis on Clostridioides difficile recurrence in critically ill adults
por: Connor, Kathryn A, et al.
Publicado: (2020)

62. Secondary Prophylaxis in Clostridioides difficile Infections: a Closer Look at Outcomes
por: Rodriguez, Rubi, et al.
Publicado: (2021)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

696. Effectiveness of Oral Vancomycin as Prophylaxis against Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant Patients
por: Reitmeyer, Kelly M, et al.
Publicado: (2023)

Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge
por: Merchan, Cristian, et al.
Publicado: (2016)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

2415. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infections among High-risk Patients
por: Lew, Alison, et al.
Publicado: (2019)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
por: Maraolo, Alberto Enrico, et al.
Publicado: (2022)

2397. Effects of antimicrobial surgical prophylaxis on rates of Clostridioides difficile infection
por: Hayes, Sarah K, et al.
Publicado: (2019)

391. Evaluation of oral vancomycin treatment for hospital-acquired Clostridioides difficile infection prophylaxis in a community hospital: A retrospective cohort study
por: Meng, Qingqing, et al.
Publicado: (2022)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis
por: Muhammad, Aziz, et al.
Publicado: (2020)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

1376. Cryptococcal Infection Presenting Solely as a Pleural Effusion
por: Alpizar-Rivas, Rodolfo M, et al.
Publicado: (2021)

The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile
por: Wultańska, Dorota, et al.
Publicado: (2020)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
por: Zhang, Kevin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ok01e0cfrk67eqcm02ktl4hv93